Roche Diagnostics Gmbh

BI 836880 Dose Optimization via Biomarker and PK/PD Modeling in Advanced Solid Tumors

7 months ago

• Researchers utilized a comprehensive biomarker and modeling approach to optimize the dose of BI 836880, a VEGF/Ang-2 inhibitor, in advanced solid tumors. • Population PK/PD modeling integrated data from Phase I studies to predict BI 836880 concentrations and Ang-2 inhibition, informing dose selection. • Simulations indicated the probability of achieving target Ang-2 inhibition levels with different BI 836880 doses, supporting individualized treatment strategies. • The study demonstrates the utility of biomarker-driven modeling in optimizing drug dosing and improving outcomes in cancer therapy.